Long-term follow-up cohort of hepatitis B in China : current status and perspectives / 临床肝胆病杂志
Journal of Clinical Hepatology
;
(12): 1454-1457, 2017.
Article
in Chinese
| WPRIM
| ID: wpr-616098
ABSTRACT
Hepatitis B virus (HBV) infection is a global public health issue,especially in the Asian-Pacific region.At present,entecavir,tenofovir,and pegylated interferon are the first-line antiviral drugs recommended by related guidelines for the prevention and treatment of hepatitis B;however,different national/regional policies,economic level,coverage of health insurance,and medical level have caused the difference in antiviral regimens.Therefore,we have established a long-term follow-up cohort of hepatitis B to evaluate the efficacy of different treatment regimens,in order to improve the cure rate of hepatitis B and reduce the incidence rates of liver cirrhosis,liver cancer,and end-stage liver disease.Real-world data from cohort study help to understand the differences between guidelines and clinical practice,provide a reference for HBV guidelines,and balance clinical effect and cost-effectiveness.
Full text:
Available
Index:
WPRIM (Western Pacific)
Type of study:
Practice guideline
/
Observational study
Language:
Chinese
Journal:
Journal of Clinical Hepatology
Year:
2017
Type:
Article
Similar
MEDLINE
...
LILACS
LIS